Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 51-60

  Campbell, R Keith ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Dipeptidyl peptidase 4; Type 2 diabetes mellitus

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; KNOCKOUT MOUSE; MEDLINE; MONOTHERAPY; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOSINE DEAMINASE; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33846422352     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H459     Document Type: Review

References (88)

1. Turner RC, Cull CA, Frighi V, Holman R, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281: 2005-12.
2. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76. DOI 10.1055/s-2004-826178
3. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
4. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40.
5. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S288-303.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(suppl 1):S43-8.
7. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
8. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;41:20-1.
9. Nauck MA, Hornberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-8.
10. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004;36:775-81. DOI 10.1055/s-2004-826163
11. UKPDS Group. UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58.
12. Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 1978;46:504-10.
13. Gomis R, Novials A, Coves MJ, Casamitjana R, Malaisse WJ. Suppression by insulin treatment of glucose-induced inhibition of insulin release in non-insulin dependent diabetics. Diabetes Res Clin Pract 1989;6:191-8.
14. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotopic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-7.
15. Nauck M, Schmidt WE, Ebert R, et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 1989;69:654-2.
16. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 1999;277:R910-6.
17. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913.
18. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regulatory Peptides 2002;107:1-13.
19. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995;16:390-410.
20. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:199-206.
21. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-81.
22. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
23. Vilsbøll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4. DOI 10.1210/jc.2002-021053
24. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3-42), is a GJP receptor antagonist in vivo. J Endocrinol 2002;175:525-33.
25. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26;791-8.
26. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
27. Hughes T, Russel ME, Bolognese L, et al. NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase inhibitor (abstract 272-OR). Diabetes 2002;51(suppl 2):A67.
28. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-70.
29. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85.
30. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004;36:852-8. DOI 10.1055/s-2004-826175
31. Lewis JT, Dayanandan B, Habener JF, Kieffer TJ. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 2000;141:3710-6.
32. Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol 1999;276:E1049-54.
33. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the enteroinsular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:14843-7.
34. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-66. DOI 10.1007/s00125-004-1342-6
35. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-9.
36. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4.
37. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitor polypeptide in patients with type-2 diabetes. J Clin Invest 1993;91:301-7.
38. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001;50:2497-504.
39. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22.
40. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992;15:270-6.
41. Ørskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-61.
42. Toft-Nielsen M-B, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.
43. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
44. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 2002;51:951-7.
45. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408. DOI 10.1210/en.2002-220405
46. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-55. DOI 10.1210/en.2002-220897
47. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004;36:804-10. DOI 10.1055/s-2004-826167
48. Trümper A, Trümper K, Hörsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1)-cells. J Endocrinol 2002;174:233-46.
49. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-6.
50. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741-8.
51. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:e745-52. DOI 10.1152/ajpendo.00030.2002
52. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267-72.
53. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic function in man. Dig Dis Sci 1993;38:665-73.
54. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.
55. Zander M, Madsbad S, Modsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
56. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-9.
57. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434-8.
58. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-54. DOI 10.1055/s-2004-826158
59. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13.
60. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996;45:1524-30.
61. Nauck MA, Weber I, Bach I, et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 1998;15:937-45.
62. Reimer MK,Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717-27.
63. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998;47:1253-8.
64. Ahrén B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000;404:239-45.
65. Sudre B, Broqua P, White RB, et al. Chronic inhibition of circulating dipetidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002;51:1461-9.
66. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic- hyperinsulinemic clamp study. Diabetes 2003;51:2677-83.
67. Holst JJ, Ørskov C. The incretin approach for diabetes treatment modulation of islet hormone release by GLP-1 agonism. Diabetes 2004;53(suppl 3):S197-204.
68. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75.
69. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84. DOI 10.1210/jc.2003-031907
70. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8.
71. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80.
72. Parkes D, Jodka C, Smith P, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-lite peptide 1. Drug Dev Res 2001;53:260-7. DOI 10.1002/ddr.1195
73. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-34.
74. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
75. Kendall DM, Riddle MS, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
76. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
77. Ribel U, Larsen MO, Rolin B, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002;451:217-25.
78. Promising clinical results from liraglutide phase 2B study: providing glucose control and weight loss without hypoglycemia. Novo Nordisk Stock Exchange announcement. www.glucagon.com/LiraglutidePhase2B.pdf (accessed 2006 Jun 27).
79. Deacon CF. MK-431 (Merck). Curr Opin Invest Drugs 2005;6:419-26.
80. Aschner P, Kipnes M, Lunceford J, et al. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) (abstract PO-1995). Diabetes 2006;55(suppl 1):A462.
81. Karasik A, Charbonnel B, Liu J, et al. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes (abstract 501-P). Diabetes 2006;55(suppl 1):A119.
82. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxyl-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89. DOI 10.1021/jm0300911
83. Hughes TE, Mone MD, Russell ME, et al. NVP-DPP728 (1-[[[2-[(5- cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(s)-pyrrolidine, a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999;38:11597-603.
84. Yan-Ling LH, Sabo R, Wang Y, et al. The influence of hepatic impairment on the pharmacokinetics of vildagliptin (abstract PO 2024). Diabetes 2006;55(suppl 1):A469.
85. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at: American Diabetes Association-66th Scientific Sessions, Washington, DC, June 13, 2006.
86. Rosenstock J, Baron M, Schweizer A, Mills D, Dejager S. Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naïve patients with type 2 diabetes (T2DM) (abstract 557-P). Diabetes 2006;55(suppl 1):A133.
87. Garber A, Camisasca RP, Ehrsam E, Collober-Maugeais C, Rochotte E, Lebeaut A. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM) (abstract 121-OR). Diabetes 2006;55(suppl 1):A29.
88. Dejager S, Baron MA, Razac S, et al. Efficacy of vildagliptin in drug-naïve patients with type 2 diabetes (abstract 0791). Diabetologia 2006;49(suppl 1):479.